The EDGE

What is the (p-) value of the P-value?

R P Gale, A Hochhaus and M-J Zhang

Leukemia 2016 30: 1965-1967; advance online publication, August 26, 2016; 10.1038/leu.2016.193

Reviews

Stem Cell Leukemia: how a TALented actor can go awry on the hematopoietic stage

N C Correia, M-L Arcangeli, F Pflumio and J T Barata

Leukemia 2016 30: 1968-1978; advance online publication, June 13, 2016; 10.1038/leu.2016.169

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis OPEN

G Merlini, I Lousada, Y Ando, A Dispenzieri, M A Gertz, M Grogan, M S Maurer, V Sanchorawala, A Wechalekar, G Palladini and R L Comenzo

Leukemia 2016 30: 1979-1986; advance online publication, July 15, 2016; 10.1038/leu.2016.191

Original Articles

ACUTE MYELOID LEUKEMIA

PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy

L Cicconi, M Divona, C Ciardi, T Ottone, A Ferrantini, S Lavorgna, V Alfonso, F Paoloni, A Piciocchi, G Avvisati, F Ferrara, E Di Bona, F Albano, M Breccia, E Cerqui, M Sborgia, M G Kropp, A Santoro, A Levis, S Sica, S Amadori, M T Voso, F Mandelli and F Lo-Coco

Leukemia 2016 30: 1987-1992; advance online publication, May 2, 2016; 10.1038/leu.2016.122

ACUTE LYMPHOBLASTIC LEUKEMIA

Loss-of-function mutations of Dynamin 2 promote T-ALL by enhancing IL-7 signalling

C S Tremblay, F C Brown, M Collett, J Saw, S K Chiu, S E Sonderegger, S E Lucas, R Alserihi, N Chau, M L Toribio, M P McCormack, M Chircop, P J Robinson, S M Jane and D J Curtis

Leukemia 2016 30: 1993-2001; advance online publication, April 27, 2016; 10.1038/leu.2016.100

β-Catenin is required for T-cell leukemia initiation and MYC transcription downstream of Notch1

C Gekas, T D’Altri, R Aligué, J González, L Espinosa and A Bigas

Leukemia 2016 30: 2002-2010; advance online publication, April 29, 2016; 10.1038/leu.2016.106

CHRONIC LYMPHOCYTIC LEUKEMIA

CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia

M Dal Bo, P Bulian, R Bomben, A Zucchetto, F M Rossi, F Pozzo, E Tissino, D Benedetti, T Bittolo, P Nanni, I Cattarossi, E Zaina, H Chivilò, M Degan, F Zaja, G Pozzato, A Chiarenza, F Di Raimondo, M I Del Principe, G Del Poeta, D Rossi, G Gaidano and V Gattei

Leukemia 2016 30: 2011-2018; advance online publication, April 25, 2016; 10.1038/leu.2016.88

Effect of first-line treatment on second primary malignancies and Richter’s transformation in patients with CLL

C Maurer, P Langerbeins, J Bahlo, P Cramer, A M Fink, N Pflug, A Engelke, J von Tresckow, G Kovacs, S Stilgenbauer, C-M Wendtner, L Müller, M Ritgen, T Seiler, K Fischer, M Hallek and B Eichhorst for the German CLL Study Group

Leukemia 2016 30: 2019-2025; advance online publication, May 2, 2016; 10.1038/leu.2016.113

MULTIPLE MYELOMA, GAMMOPATHIES

Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma

V González-Calle, J Dávila, F Escalante, A G de Coca, C Aguilera, R López, A Bárez, J M Alonso, R Hernández, J M Hernández, P de la Fuente, N Puig, E M Ocio, N C Gutiérrez, R García-Sanz and M V Mateos

Leukemia 2016 30: 2026-2031; advance online publication, May 2, 2016; 10.1038/leu.2016.123

CHRONIC MYELOPROLIFERATIVE NEOPLASMS

High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists

V De Stefano, M Ruggeri, F Cervantes, A Alvarez-Larrán, A Iurlo, M L Randi, E Elli, M C Finazzi, G Finazzi, E Zetterberg, N Vianelli, G Gaidano, E Rossi, S Betti, I Nichele, D Cattaneo, M Palova, M H Ellis, R Cacciola, A Tieghi, J C Hernandez-Boluda, E Pungolino, G Specchia, D Rapezzi, A Forcina, C Musolino, A Carobbio, M Griesshammer, E Sant’Antonio, A M Vannucchi and T Barbui

Leukemia 2016 30: 2032-2038; advance online publication, April 26, 2016; 10.1038/leu.2016.85

STEM CELL BIOLOGY

Smad4 in osteoblasts exerts a differential impact on HSC fate depending on osteoblast maturation stage

S-H Kook, C-Y Yun, H-J Sim, G Bhattarai, B-C Lee, K-Y Lee, E-S Cho and J-C Lee

Leukemia 2016 30: 2039-2046; advance online publication, May 20, 2016; 10.1038/leu.2016.133

STEM CELL TRANSPLANTATION

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party

M Sobh, M Michallet, G Gahrton, S Iacobelli, A van Biezen, S Schönland, E Petersen, N Schaap, F Bonifazi, L Volin, E Meijer, D Niederwieser, J ElCheikh, R Tabrizi, N Fegeux, J Finke, D Bunjes, J Cornelissen, H Einsele, B Bruno, M Potter, R Fanin, M Mohty, L Garderet and N Kröger

Leukemia 2016 30: 2047-2054; advance online publication, April 27, 2016; 10.1038/leu.2016.101

Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant

Y Wang, H-X Wang, Y-R Lai, Z-M Sun, D-P Wu, M Jiang, D-H Liu, K-L Xu, Q-F Liu, L Liu, J-B Wang, F Gao, J Ou-Yang, S-J Gao, L-P Xu and X-J Huang

Leukemia 2016 30: 2055-2063; advance online publication, May 2, 2016; 10.1038/leu.2016.110

ANIMAL MODELS

Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model

P Sontakke, M Carretta, J Jaques, A Z Brouwers-Vos, L Lubbers-Aalders, H Yuan, J D de Bruijn, A C M Martens, E Vellenga, R W J Groen and J J Schuringa

Leukemia 2016 30: 2064-2073; advance online publication, April 29, 2016; 10.1038/leu.2016.108

Letters to the Editor

Novel regulators in hematopoietic stem cells can be revealed by a functional approach under leukemic condition

H Cheng, Y Liu, Q Jia, S Ma, W Yuan, H Jia and T Cheng

Leukemia 2016 30: 2074-2077; advance online publication, May 2, 2016; 10.1038/leu.2016.118

A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children’s Oncology Group

L Eidenschink Brodersen, T A Alonzo, A J Menssen, R B Gerbing, L Pardo, A P Voigt, S B Kahwash, B Hirsch, S Raimondi, A S Gamis, S Meshinchi and M R Loken

Leukemia 2016 30: 2077-2080; advance online publication, May 2, 2016; 10.1038/leu.2016.119

Effect of measurable (‘minimal’) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia

M Othus, B L Wood, D L Stirewalt, E H Estey, S H Petersdorf, F R Appelbaum, H P Erba and R B Walter

Leukemia 2016 30: 2080-2083; advance online publication, May 2, 2016; 10.1038/leu.2016.120

Germline heterozygous DDX41 variants in a subset of familial myelodysplasia and acute myeloid leukemia OPEN

S R Cardoso, G Ryan, A J Walne, A Ellison, R Lowe, H Tummala, A Rio-Machin, L Collopy, A Al Seraihi, Y Wallis, P Page, S Akiki, J Fitzgibbon, T Vulliamy and I Dokal

Leukemia 2016 30: 2083-2086; advance online publication, June 2, 2016; 10.1038/leu.2016.124

Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation

S Dietrich, H Finel, C Martinez, J Tischer, D Blaise, P Chevallier, L Castagna, N Milpied, A Bacigalupo, P Corradini, M Mohty, M Sanz, A Hausmann, S Montoto, S Robinson, A Boumendil, A Sureda and P Dreger on behalf of the EBMT Lymphoma Working Party

Leukemia 2016 30: 2086-2089; advance online publication, May 5, 2016; 10.1038/leu.2016.125

Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias OPEN

D B Lipka, M-C Wagner, M Dziadosz and T Fischer

Leukemia 2016 30: 2090-2093; advance online publication, May 3, 2016; 10.1038/leu.2016.127

Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia

B M Richine, E L Virts, J D Bowling, B Ramdas, R Mali, R Naoye, Z Liu, Z-Y Zhang, H S Boswell, R Kapur and R J Chan

Leukemia 2016 30: 2094-2097; advance online publication, May 20, 2016; 10.1038/leu.2016.131

Overexpression of FLT3-ITD driven by spi-1 results in expanded myelopoiesis with leukemic phenotype in zebrafish

J-W Lu, H-A Hou, M-S Hsieh, H-F Tien and L-I Lin

Leukemia 2016 30: 2098-2101; advance online publication, May 20, 2016; 10.1038/leu.2016.132

Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide

S R McCurdy, B S Iglehart, D A Batista, C D Gocke, Y Ning, H A Knaus, A M Jackson, M S Leffell, L Luznik and I Gojo

Leukemia 2016 30: 2102-2106; advance online publication, May 23, 2016; 10.1038/leu.2016.144

Activation of wnt/β-catenin signaling blocks monocyte–macrophage differentiation through antagonizing PU.1-targeted gene transcription

Y Sheng, W Ju, Y Huang, J Li, H Ozer, X Qiao and Z Qian

Leukemia 2016 30: 2106-2109; advance online publication, May 23, 2016; 10.1038/leu.2016.146

The new provisional WHO entity ‘RUNX1 mutated AML’ shows specific genetics but no prognostic influence of dysplasia OPEN

T Haferlach, A Stengel, S Eckstein, K Perglerová, T Alpermann, W Kern, C Haferlach and M Meggendorfer

Leukemia 2016 30: 2109-2112; advance online publication, May 23, 2016; 10.1038/leu.2016.150

Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML

H Wu, A Wang, Z Qi, X Li, C Chen, K Yu, F Zou, C Hu, W Wang, Z Zhao, J Wu, J Liu, X Liu, L Wang, W Wang, S Zhang, R M Stone, I A Galinsky, J D Griffin, D Weinstock, A Christodoulou, H Wang, Y Shen, Z Zhai, E L Weisberg, J Liu and Q Liu

Leukemia 2016 30: 2112-2116; advance online publication, May 25, 2016; 10.1038/leu.2016.151

Inhibition of precursor B-cell malignancy progression by toll-like receptor ligand-induced immune responses

M Fidanza, A E Seif, A DeMicco, N Rolf, S Jo, B Yin, Y Li, D M Barrett, J Duque-Afonso, M L Cleary, C H Bassing, S A Grupp and G S D Reid

Leukemia 2016 30: 2116-2119; advance online publication, May 25, 2016; 10.1038/leu.2016.152

The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK

J Rudolph, A Heine, T Quast, W Kolanus, J Trebicka, P Brossart and D Wolf

Leukemia 2016 30: 2119-2123; advance online publication, May 25, 2016; 10.1038/leu.2016.155

Robustness of comprehensive DNA- and RNA-based assays at diagnosis of acute myeloid leukemia using blood and bone marrow stored on filter cards

T Haferlach, S Weber, R Konietschke, N Nadarajah, A Stengel, W Kern, C Haferlach and M Meggendorfer

Leukemia 2016 30: 2123-2125; advance online publication, May 25, 2016; 10.1038/leu.2016.156